CERo Therapeutics Holdings, Inc.
CERO
$0.01
$0.00-9.91%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.07% | -0.76% | 0.22% | 41.99% | 56.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.42% | 23.05% | 14.93% | 37.86% | 74.10% |
| Operating Income | -17.42% | -23.05% | -14.93% | -37.86% | -74.10% |
| Income Before Tax | -86.31% | -139.87% | -43.61% | -91.22% | -58.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.31% | -139.87% | -43.61% | -91.22% | -58.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.31% | -139.87% | -43.61% | -91.22% | -58.57% |
| EBIT | -17.42% | -23.05% | -14.93% | -37.86% | -74.10% |
| EBITDA | -18.66% | -24.68% | -16.37% | -40.18% | -78.44% |
| EPS Basic | 76.27% | 69.30% | 49.73% | -102.08% | -169.12% |
| Normalized Basic EPS | 93.47% | 83.59% | 65.89% | -265.53% | -249.14% |
| EPS Diluted | 76.27% | 69.30% | 49.73% | -102.08% | -169.12% |
| Normalized Diluted EPS | 93.47% | 83.59% | 65.89% | -265.53% | -249.14% |
| Average Basic Shares Outstanding | 17,859.38% | 14,013.02% | 3,060.29% | 1,856.20% | 568.34% |
| Average Diluted Shares Outstanding | 15,521.94% | 10,621.24% | 1,869.68% | 149.97% | -39.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |